今年最重要的进展:卵巢癌
Melissa A Lumish1, Elise C Kohn2, William P Tew1
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Cancer
|December 15, 2023
概括
卵巢癌系统疗法的近期进展提供了延长生存时间,包括新的抗体-药物合物和多 (ADP-ribose) 聚合酶抑制剂的维护益处. 然而,优化晚期卵巢癌的治疗以提高治愈率仍然存在挑战.
科学领域:
- 妇科瘤学 妇科瘤学
- 医学瘤学 医学瘤学
- 翻译癌症研究 翻译癌症研究
背景情况:
- 卵巢癌治愈率仍然很低,有效查策略有限.
- 最近的全身疗法进展表明,有潜力延长卵巢癌患者的存活时间.
研究的目的:
- 审查最近在卵巢癌全身疗法方面的进展.
- 评估新疗法对生存率和治愈率的影响.
主要方法:
- 审查最近的临床试验和FDA批准的卵巢癌全身疗法.
- 分析了来自多 (ADP-ribose) 聚合酶抑制剂试验的长期随访数据.
- 对敏感卵巢癌和罕见组织学研究的评估.
主要成果:
- 美国食品和药物管理局将于2022年加速批准首个针对白金耐药卵巢癌的抗体-药物合物.
- 在前期设置中,通过维护聚聚烯酸 (ADP-ribose) 聚合酶抑制剂,证明了整体生存益处.
- 在非治疗的环境中,报告了从非治疗环境中的多聚聚合酶抑制剂 (ADP-ribose) 试验中生存损害,导致禁用指示.
- 几项试验未能显示对敏感卵巢癌和罕见组织学有显著益处.
结论:
- 虽然新疗法,如抗体药物合物和PARP抑制剂显示出希望,优化晚期卵巢癌的全身疗法仍然是一个关键的挑战.
- 需要进一步的研究,以改善长期存活率,并在卵巢癌中实现更高的治愈率.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355


